Capricor Therapeutics Faces Securities Class Action Over Deramiocel Data

The complaint centers on allegations that Capricor violated the Securities Exchange Act of 1934 by issuing false and misleading statements to shareholders. Specifically, the company is accused of unilaterally modifying the statistical analysis plan for clinical data related to Deramiocel. According to the filing, Capricor moved forward with a resubmitted Biologics License Application for the drug without first securing necessary agreement from the U.S. Food and Drug Administration.

These actions form the basis of the legal challenge, which asserts that public disclosures during the specified period failed to reflect the true regulatory status of the development program. Shareholders seeking to participate in the litigation or discuss potential lead plaintiff appointments must take action by the September 28, 2026, deadline. Attorney David J. Schwartz of the DJS Law Group is representing the interests of those who suffered losses due to the alleged omissions.